Jean‐Yves Blay

95.1k total citations · 22 hit papers
1.2k papers, 45.8k citations indexed

About

Jean‐Yves Blay is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Jean‐Yves Blay has authored 1.2k papers receiving a total of 45.8k indexed citations (citations by other indexed papers that have themselves been cited), including 769 papers in Pulmonary and Respiratory Medicine, 466 papers in Oncology and 280 papers in Gastroenterology. Recurrent topics in Jean‐Yves Blay's work include Sarcoma Diagnosis and Treatment (577 papers), Gastrointestinal Tumor Research and Treatment (280 papers) and Vascular Tumors and Angiosarcomas (166 papers). Jean‐Yves Blay is often cited by papers focused on Sarcoma Diagnosis and Treatment (577 papers), Gastrointestinal Tumor Research and Treatment (280 papers) and Vascular Tumors and Angiosarcomas (166 papers). Jean‐Yves Blay collaborates with scholars based in France, United States and United Kingdom. Jean‐Yves Blay's co-authors include Paolo G. Casali, Axel Le Cesne, Jaap Verweij, Isabelle Ray‐Coquard, Axel Le Cesne, Ian Judson, M. van Glabbeke, Peter Reichardt, Christine Ménétrier‐Caux and Antoîne Italiano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Jean‐Yves Blay

1.1k papers receiving 44.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 1.3k citations Jaap Verweij, Paolo G. Casali et al. profile →
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2014 814 citations Jaap Verweij, Hans Gelderblom et al. profile →
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations Maria Dêbiec‐Rychter, Raf Sciot et al. profile →
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

2009 624 citations Isabelle Ray‐Coquard, M. van Glabbeke et al. Cancer Research profile →
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

2009 562 citations Michael Gobert, Isabelle Treilleux et al. Cancer Research profile →
Consensus meeting for the management of gastrointestinal stromal tumors  Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

2005 561 citations Jean‐Yves Blay, Paolo G. Casali et al. profile →
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

2016 539 citations Patrick Schöffski, Sant P. Chawla et al. profile →
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

2010 516 citations David M. Thomas, Sant P. Chawla et al. profile →
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

2010 486 citations Jaap Verweij, Jean‐Yves Blay et al. profile →
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

2012 455 citations Isabelle Ray‐Coquard, Jean‐Yves Blay et al. profile →
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

2013 430 citations Sant P. Chawla, Jean‐Yves Blay et al. profile →
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

2009 397 citations George D. Demetri, Sant P. Chawla et al. Journal of Clinical Oncology profile →
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010 382 citations Paolo G. Casali, Jean‐Yves Blay profile →
Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

2011 382 citations Jean‐Yves Blay, Isabelle Ray‐Coquard et al. profile →
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2012 332 citations Daniel Branstetter, Scott D. Nelson et al. Clinical Cancer Research profile →
Deep learning-based classification of mesothelioma improves prediction of patient outcome

2019 314 citations Jean‐Yves Blay et al. profile →
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

2015 310 citations Jean‐Yves Blay et al. profile →
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

2020 251 citations Jean‐Yves Blay, Hans Gelderblom et al. profile →
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

2018 229 citations Florence Duffaud, Olivier Mir et al. profile →
Gastrointestinal stromal tumours

2021 217 citations Jean‐Yves Blay et al. profile →
Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

2022 174 citations Jean‐Yves Blay et al. profile →

Peers

Countries citing papers authored by Jean‐Yves Blay

Since Specialization

Citations

This map shows the geographic impact of Jean‐Yves Blay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Yves Blay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Yves Blay more than expected).

Fields of papers citing papers by Jean‐Yves Blay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Yves Blay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Yves Blay. The network helps show where Jean‐Yves Blay may publish in the future.

Co-authorship network of co-authors of Jean‐Yves Blay

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Yves Blay. A scholar is included among the top collaborators of Jean‐Yves Blay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Yves Blay. Jean‐Yves Blay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study 2023 ·ESMO Open ·Axel Le Cesne, Christine Chevreau, Christophe Perrin, Antoîne Italiano, Alice Hervieu, Jean‐Yves Blay, Sophie Piperno‐Neumann, Esma Saâda-Bouzid, François Bertucci, Nelly Firmin, Elsa Kalbacher, (unknown), Camille Schiffler, (unknown), Marta Jimenez, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Florence Duffaud	9
2	Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG 2023 ·Bulletin du Cancer ·Andy Karabajakian, Catherine Genestie, Pierre Méeus, Frédéric Guyon, C. Llacer Moscardo, Sabrina Croce, S. Taïeb, Florence Duffaud, Patricia Pautier, Isabelle Ray‐Coquard, Jean‐Yves Blay	2
3	EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Spleen: Report of an Aggressive Form With Molecular Characterization 2023 ·International Journal of Surgical Pathology ·(unknown), Paul Legendre, (unknown), (unknown), Barbara Burroni, (unknown), Tali‐Anne Szwebel, N. Costedoat‐Chalumeau, Karen Leroy, Hélène Blons, Jean‐Yves Blay, Pascaline Boudou‐Rouquette, Benjamin Terrier	3
4	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study 2019 ·Clinical Cancer Research ·Maud Toulmonde, Jean‐Yves Blay, Olivier Bouché, Olivier Mir, Nicolas Penel, Nicolás Isambert, Florence Duffaud, Emmanuelle Bompas, (unknown), Romain Boidot, (unknown), François Ghiringhelli, Carlo Lucchesi, Carine Bellera, François Le Loarer, Antoîne Italiano	14
5	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) 2019 ·Clinical Cancer Research ·Roberta Sanfilippo, Robin L. Jones, Jean‐Yves Blay, Axel Le Cesne, Salvatore Provenzano, Γεώργιος Αντωνίου, Olivier Mir, Giovanni Fucà, Elena Fumagalli, Rossella Bertulli, Silvia Stacchiotti, Mehdi Brahmi, Federica Grosso, Armelle Dufresne, Nadia Hindi, Marta Sbaraglia, Alessandro Gronchi, Paola Collini, Angelo Paolo Dei Tos, Paolo G. Casali	75
6	Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials 2019 ·Clinical Cancer Research ·Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean‐Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. van Erp, Hans Gelderblom, Winette T.A. van der Graaf, Alessandro Gronchi	64
7	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine 2017 ·Journal of Clinical Oncology ·George D. Demetri, Patrick Schöffski, Giovanni Grignani, Jean‐Yves Blay, Robert G. Maki, Brian A. Van Tine, Thierry Alcindor, Robin L. Jones, David R. D’Adamo, Matthew Guo, Sant P. Chawla	129
8	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST 2014 ·Clinical Cancer Research ·Agnieszka Woźniak, Piotr Rutkowski, Patrick Schöffski, Isabelle Ray‐Coquard, Isabelle Hostein, Hans‐Ulrich Schildhaus, Axel Le Cesne, Elżbieta Bylina, Janusz Limon, Jean‐Yves Blay, Janusz A. Siedlecki, Eva Wardelmann, Raf Sciot, Jean‐Michel Coindre, Maria Dêbiec‐Rychter	121
9	Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment 2013 ·Cancer Research ·Isabelle Le Mercier, Dominique Poujol, Amélien Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean‐Yves Blay, Nathalie Bendriss‐Vermare, Christophe Caux, Isabelle Puisieux, Nadège Goutagny	156
10	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells 2012 ·Cancer Research ·Julien Faget, Nathalie Bendriss‐Vermare, Michael Gobert, Isabelle Durand, Daniel Olive, Cathy Biota, Thomas Bachelot, Isabelle Treilleux, Sophie Goddard‐Léon, Emilie Lavergne, Sylvie Chabaud, Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	159
11	Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression 2012 ·Cancer Research ·Vanja Sisirak, Julien Faget, Michael Gobert, Nadège Goutagny, Nelly Vey, Isabelle Treilleux, Sarah Renaudineau, Gaelle Poyet, Sana Intidhar Labidi‐Galy, Sophie Goddard‐Léon, Isabelle Durand, Isabelle Le Mercier, Agathe Bajard, Thomas Bachelot, Alain Puisieux, Isabelle Puisieux, Jean‐Yves Blay, Christine Ménétrier‐Caux, Christophe Caux, Nathalie Bendriss‐Vermare	269
12	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone breakdown → 2012 ·Clinical Cancer Research ·Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean‐Yves Blay, Sant P. Chawla, David M. Thomas, Susie Jun, Ira Jacobs	332
13	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure 2012 ·Clinical Cancer Research ·George D. Demetri, (unknown), Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio López–Pousa, Axel Le Cesne, David S. Goldstein, Luis Paz‐Ares, Jean‐Yves Blay, Grant A. McArthur, Qiang Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali	102
14	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) 2012 ·The Oncologist ·Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, Axel Le Cesne, Y Robin, Christine Chevreau, Jacques‐Olivier Bay, Guilhem Bousquet, Sophie Piperno‐Neumann, Nicolás Isambert, L. Lemaître, Charles Fournier, Eric Gauthier, Olivier Collard, Didier Cupissol, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel, (unknown)	148
15	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer 2011 ·Cancer Research ·Sana Intidhar Labidi‐Galy, Vanja Sisirak, Pierre Méeus, Michael Gobert, Isabelle Treilleux, Agathe Bajard, Jean‐Damien Combes, Julien Faget, François Mithieux, (unknown), Olivier Trédan, Isabelle Durand, Christine Ménétrier‐Caux, Christophe Caux, Jean‐Yves Blay, Isabelle Ray‐Coquard, Nathalie Bendriss‐Vermare	187
16	Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells 2011 ·Cancer Research ·Julien Faget, Cathy Biota, Thomas Bachelot, Michael Gobert, Isabelle Treilleux, Nadège Goutagny, Isabelle Durand, (unknown), Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	103
17	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome breakdown → 2009 ·Cancer Research ·Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, Thomas Bachelot, Sophie Goddard‐Léon, Vanessa Arfi, Cathy Biota, (unknown), Isabelle Durand, Daniel Olive, Solène Perez, Nicolas Pasqual, Christelle Fauré, Isabelle Ray‐Coquard, Alain Puisieux, Christophe Caux, Jean‐Yves Blay, Christine Ménétrier‐Caux	562
18	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) breakdown → 2009 ·Journal of Clinical Oncology ·Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Axel Le Cesne, Michelle Scurr, Patrick Schöffski, Françoise Collin, Lini Pandite, Sandrine Marréaud, (unknown), M. van Glabbeke, Jaap Verweij, Jean‐Yves Blay	535
19	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study 2007 ·Journal of Clinical Oncology ·Paul Lorigan, Jaap Verweij, Zsuzsa Pápai, Sjoerd Rodenhuis, Axel Le Cesne, Michael Leahy, John Radford, M. M. Van Glabbeke, Anne Kirkpatrick, Pancras C.W. Hogendoorn, Jean‐Yves Blay	192
20	Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients 2004 ·Journal of Clinical Oncology ·Alejandro Yovine, M. Riofrio, Jean‐Yves Blay, Étienne Brain, Jérôme Alexandre, Carmen Kahatt, A. Taamma, José Jimeno, C. Martin, Yacine Salhi, Esteban Cvitkovic, J. L. Misset	261

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact